Literature DB >> 18721000

Applications of metabolomics in drug discovery and development.

David S Wishart1.   

Abstract

Metabolomics is a relatively new field of 'omics' technology that is primarily concerned with the global or system-wide characterization of small molecule metabolites using technologies such as nuclear magnetic resonance, liquid chromatography and/or mass spectrometry. Its unique focus on small molecules and the physiological effects of small molecules aligns the field of metabolomics very closely with the aims and interests of many researchers in the pharmaceutical industry. Because of its conceptual and technical overlap with many aspects of pharmaceutical research, metabolomics is now finding applications that span almost the full length of the drug discovery and development pipeline, from lead compound discovery to post-approval drug surveillance. This review explores some of the most interesting or significant applications of metabolomics as they relate to pharmaceutical research and development. Specific examples are given that show how metabolomics can be used to facilitate lead compound discovery, to improve biomarker identification (for monitoring disease status and drug efficacy) and to monitor drug metabolism and toxicity. Other applications are also discussed, including the use of metabolomics to facilitate clinical trial testing and to improve post-approval drug monitoring. These examples show that metabolomics potentially offer drug researchers and drug regulators an effective, inexpensive route to addressing many of the riskier or more expensive issues associated with the discovery, development and monitoring of drug products.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18721000     DOI: 10.2165/00126839-200809050-00002

Source DB:  PubMed          Journal:  Drugs R D        ISSN: 1174-5886


  44 in total

1.  Chronic caloric restriction partially protects against age-related alteration in serum metabolome.

Authors:  Jennifer M De Guzman; Ginger Ku; Ryan Fahey; Yun-Hee Youm; Ignatius Kass; Donald K Ingram; Vishwa Deep Dixit; Indu Kheterpal
Journal:  Age (Dordr)       Date:  2012-06-04

2.  Global metabolic profiling procedures for urine using UPLC-MS.

Authors:  Elizabeth J Want; Ian D Wilson; Helen Gika; Georgios Theodoridis; Robert S Plumb; John Shockcor; Elaine Holmes; Jeremy K Nicholson
Journal:  Nat Protoc       Date:  2010-06       Impact factor: 13.491

3.  Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.

Authors:  Patrick-Denis St-Coeur; Julie J Poitras; Miroslava Cuperlovic-Culf; Mohamed Touaibia; Pier Morin
Journal:  J Neurooncol       Date:  2015-08-28       Impact factor: 4.130

4.  Advances in Nuclear Magnetic Resonance for Drug Discovery.

Authors:  Robert Powers
Journal:  Expert Opin Drug Discov       Date:  2009-10-01       Impact factor: 6.098

Review 5.  Database resources in metabolomics: an overview.

Authors:  Eden P Go
Journal:  J Neuroimmune Pharmacol       Date:  2009-05-07       Impact factor: 4.147

Review 6.  New tools and new biology: recent miniaturized systems for molecular and cellular biology.

Authors:  Morgan Hamon; Jong Wook Hong
Journal:  Mol Cells       Date:  2013-12-02       Impact factor: 5.034

7.  Metabolomic analysis and visualization engine for LC-MS data.

Authors:  Eugene Melamud; Livia Vastag; Joshua D Rabinowitz
Journal:  Anal Chem       Date:  2010-11-04       Impact factor: 6.986

8.  Towards automatic metabolomic profiling of high-resolution one-dimensional proton NMR spectra.

Authors:  Pascal Mercier; Michael J Lewis; David Chang; David Baker; David S Wishart
Journal:  J Biomol NMR       Date:  2011-03-01       Impact factor: 2.835

9.  Biomarker Validation for Aging: Lessons from mtDNA Heteroplasmy Analyses in Early Cancer Detection.

Authors:  Peter E Barker; Mahadev Murthy
Journal:  Biomark Insights       Date:  2009-11-27

Review 10.  21st century natural product research and drug development and traditional medicines.

Authors:  Linh T Ngo; Joseph I Okogun; William R Folk
Journal:  Nat Prod Rep       Date:  2013-04       Impact factor: 13.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.